A 58-year-old postmenopausal woman from Delhi presents with progressive back pain and loss of height over the past 2 years. She reports a fall from standing height 6 months ago that resulted in a wrist fracture. On examination, she has kyphosis and height loss of 4 cm compared to her driver's license. Serum calcium is 8.8 mg/dL, phosphate 3.5 mg/dL, alkaline phosphatase 65 U/L, and 25-OH vitamin D is 18 ng/mL. DEXA scan shows T-score of −2.8 at the lumbar spine. Which of the following is the most appropriate first-line pharmacological intervention?

Explanation

## Clinical Assessment This patient presents with established osteoporosis (T-score ≤ −2.5) with fragility fracture, meeting diagnostic criteria for treatment initiation. ### Key Diagnostic Features **Key Point:** The combination of postmenopausal status, multiple fragility fractures (wrist, vertebral compression suggested by kyphosis), height loss, and DEXA-confirmed osteoporosis (T-score −2.8) mandates pharmacological therapy. **High-Yield:** Vitamin D insufficiency (18 ng/mL; normal >30 ng/mL) is present but is a *cofactor* for treatment, not a substitute for it. Calcium and vitamin D alone are inadequate for established osteoporosis with fracture history. ## Treatment Algorithm ```mermaid flowchart TD A[Postmenopausal woman with osteoporosis + fragility fracture]:::outcome A --> B{Vitamin D status?}:::decision B -->|Deficient| C[Replete vitamin D first]:::action C --> D[Then initiate bisphosphonate]:::action B -->|Sufficient| E[Start bisphosphonate directly]:::action D --> F[Alendronate 70 mg weekly]:::action E --> F F --> G[Reassess DEXA at 2 years]:::outcome ``` ### Why Alendronate? | Feature | Alendronate | Teriparatide | Raloxifene | |---------|-------------|-------------|----------| | **First-line status** | Yes (WHO, NAMS) | Second-line (severe osteoporosis, multiple fractures) | Alternative for women intolerant to bisphosphonates | | **Fracture reduction** | Hip, spine, wrist (50–70%) | Spine & non-spine (65%) | Spine only (30%) | | **Cost** | Low | Very high | Moderate | | **Dosing** | Weekly | Daily injection | Daily oral | | **Contraindications** | Esophageal stricture, inability to sit upright | Hypercalcemia, Paget's disease | VTE risk, immobility | **Clinical Pearl:** Although this patient has vitamin D insufficiency, the standard approach is to *concurrently* replete vitamin D (target 25-OH vitamin D >30 ng/mL) while starting a bisphosphonate. Waiting to replete vitamin D alone delays fracture prevention. **Mnemonic — First-line agents for osteoporosis:** **BRAT** = **B**isphosphonates (alendronate, risedronate), **R**aloxifene, **A**nti-RANKL (denosumab), **T**eriparatide. Bisphosphonates are first-line for postmenopausal women with fracture history [cite:Harrison 21e Ch 397]. ## Why This Patient Needs Alendronate 1. **Established osteoporosis** (T-score −2.8) + **fragility fracture** = high 10-year fracture risk 2. **Postmenopausal** status (rapid bone loss phase) 3. **Alendronate** has the strongest evidence for hip and vertebral fracture reduction in this demographic 4. **Cost-effectiveness** and **oral convenience** (weekly dosing) improve compliance ## Counseling Points - Take alendronate on empty stomach, 30 min before food, with full glass of water - Remain upright for 30 min post-dose (prevent esophageal irritation) - Concurrent calcium 1000–1200 mg/day + vitamin D3 800–1000 IU/day (or replete to >30 ng/mL) - Expect bone density improvement at 2 years; reassess with DEXA - Monitor for atypical femoral fractures (rare, <1 per 1000 patient-years) and osteonecrosis of jaw (very rare in osteoporosis dosing) **Warning:** Do NOT delay bisphosphonate therapy while waiting for vitamin D repletion alone — fracture risk remains high during that window.